NIH Should Open Patents For Abbott HIV Drug, Petition Says

Law360, New York (October 29, 2012, 6:39 PM EDT) -- Four organizations on Thursday petitioned the National Institutes of Health for march-in rights for the patents to Abbott Laboratories' Norvir, a drug used to treat HIV, arguing that NIH should grant such rights when a patented drug costs much more in the U.S. than in other industrialized countries.

Federal agencies, under the Bayh-Dole Act, can grant march-in rights, or in other words, ignore patent exclusivity, when an invention is federally funded and certain other conditions are met. No agency has ever done so.

The groups — the American...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.